RBC Capital Markets Restated Sector Performer Rating For IWG Plc (LON:IWG); Genocea Biosciences (GNCA) Sellers Increased By 72.81% Their Shorts

Genocea Biosciences, Inc. (NASDAQ:GNCA) Logo

IWG Plc (LON:IWG) stock Sector Performer was maintained at RBC Capital Markets in a note issued to clients on Monday, 14 May.

Genocea Biosciences Inc (NASDAQ:GNCA) had an increase of 72.81% in short interest. GNCA’s SI was 3.81 million shares in May as released by FINRA. Its up 72.81% from 2.21M shares previously. With 1.10M avg volume, 4 days are for Genocea Biosciences Inc (NASDAQ:GNCA)’s short sellers to cover GNCA’s short positions. The SI to Genocea Biosciences Inc’s float is 16.81%. The stock increased 0.21% or $0.0019 during the last trading session, reaching $0.9156. About 307,462 shares traded. Genocea Biosciences, Inc. (NASDAQ:GNCA) has declined 81.61% since May 14, 2017 and is downtrending. It has underperformed by 93.16% the S&P500.

IWG Plc, together with its subsidiaries, provides office outsourcing services in the Americas, Europe, the Middle East, Africa, the Asia Pacific, and the United Kingdom. The company has market cap of 2.78 billion GBP. The firm offers various workplace formats, including office spaces, co-working spaces, business lounges, meeting rooms, day offices, virtual offices, and mobile sites, as well as workplace recovery services. It has a 24.86 P/E ratio. The Company’s sites provide network monitoring, enterprise-level connectivity, IT helpdesks, firewall security, reception, food and beverage, and facilities management services.

Among 7 analysts covering IWG Plc (LON:IWG), 1 have Buy rating, 1 Sell and 5 Hold. Therefore 14% are positive. IWG Plc has GBX 435 highest and GBX 200 lowest target. GBX 241.67’s average target is -20.97% below currents GBX 305.8 stock price. IWG Plc had 31 analyst reports since March 14, 2017 according to SRatingsIntel. As per Monday, October 23, the company rating was downgraded by Berenberg. The rating was downgraded by Credit Suisse on Monday, October 23 to “Neutral”. The company was maintained on Monday, February 5 by Credit Suisse. Credit Suisse maintained IWG PLC (LON:IWG) rating on Monday, March 12. Credit Suisse has “Neutral” rating and GBX 260 target. On Friday, October 20 the stock rating was maintained by Numis Securities with “Hold”. Berenberg maintained the stock with “Hold” rating in Wednesday, March 14 report. The stock of IWG PLC (LON:IWG) earned “Hold” rating by Numis Securities on Thursday, November 2. The stock has “Overweight” rating by JP Morgan on Tuesday, March 21. Peel Hunt downgraded it to “Add” rating and GBX 399 target in Tuesday, August 8 report. The company was maintained on Monday, January 22 by Peel Hunt.

The stock increased 21.35% or GBX 53.8 during the last trading session, reaching GBX 305.8. About 12.27 million shares traded or 437.39% up from the average. IWG PLC (LON:IWG) has 0.00% since May 14, 2017 and is . It has underperformed by 11.55% the S&P500.

Among 9 analysts covering Genocea Biosciences (NASDAQ:GNCA), 8 have Buy rating, 0 Sell and 1 Hold. Therefore 89% are positive. Genocea Biosciences had 20 analyst reports since August 6, 2015 according to SRatingsIntel. The stock of Genocea Biosciences, Inc. (NASDAQ:GNCA) has “Buy” rating given on Tuesday, August 11 by Needham. The stock of Genocea Biosciences, Inc. (NASDAQ:GNCA) has “Overweight” rating given on Thursday, August 6 by Piper Jaffray. The firm earned “Hold” rating on Tuesday, September 26 by Needham. The firm earned “Buy” rating on Thursday, December 17 by UBS. Cowen & Co maintained Genocea Biosciences, Inc. (NASDAQ:GNCA) on Wednesday, August 9 with “Buy” rating. The rating was upgraded by Needham to “Buy” on Tuesday, February 6. The stock of Genocea Biosciences, Inc. (NASDAQ:GNCA) has “Hold” rating given on Tuesday, September 26 by Stifel Nicolaus. The firm earned “Buy” rating on Monday, April 30 by H.C. Wainwright. Needham maintained the stock with “Buy” rating in Thursday, September 29 report. The stock of Genocea Biosciences, Inc. (NASDAQ:GNCA) earned “Buy” rating by Cowen & Co on Monday, July 24.

Genocea Biosciences, Inc., a biopharmaceutical company, engages in developing T cell-directed vaccines and immunotherapies to treat infectious diseases and cancer. The company has market cap of $79.28 million. The firm uses AnTigen Lead Acquisition System , its proprietary discovery platform to build a pipeline of immunotherapies and its first neoantigen cancer vaccine. It currently has negative earnings. The Company’s lead product candidate is GEN-003, a therapeutic vaccine or immunotherapy that is in Phase 2 trial for the treatment of genital herpes infections.

More important recent Genocea Biosciences, Inc. (NASDAQ:GNCA) news were published by: Globenewswire.com which released: “Market Trends Toward New Normal in City Office REIT, Malibu Boats, Vical, Renasant, Genocea Biosciences, and …” on May 02, 2018, also Globenewswire.com published article titled: “Genocea to Host First Quarter 2018 Financial Results Conference Call & Webcast on May 10, 2018 at 9 am ET”, Nasdaq.com published: “Genocea Files Investigational New Drug Application for Neoantigen Cancer Vaccine Candidate GEN-009” on April 30, 2018. More interesting news about Genocea Biosciences, Inc. (NASDAQ:GNCA) was released by: Streetinsider.com and their article: “Genocea Biosciences (GNCA) Highlights Data from ATLAS Platform at 2018 AACR Meetings” with publication date: April 18, 2018.

Genocea Biosciences, Inc. (NASDAQ:GNCA) Ratings Chart